Background and objective: Although idiopathic pulmonary fibrosis (IPF) patients experience a worse survival compared with chronic hypersensitivity pneumonitis (CHP), organic dust exposure is a known risk factor for both IPF and CHP. Methods: We divided patients diagnosed with IPF, based on their exposure to moulds/birds (absent: group A; present: group B). We retrospectively compared pulmonary function and survival between groups A and B, and a separate CHP cohort (group C). Results: A total of 293 patients were included (group A: n = 171, group B: n = 73, group C: n = 49). Demographics and baseline pulmonary function did not differ between groups A and B, but significant differences were seen between groups B and C. Median survival of group B was 84 months, which was longer than group A (43 months, P = 0.002), but lower than group C (157 months, P = 0.04), in both univariate and multivariate analyses. Antifibrotic treatment resulted in a better outcome in group A (hazard ratio (HR): 0.44) and group B (HR: 0.12) without interaction between exposure and antifibrotic use (P = 0.20). Forced vital capacity (FVC) decline was not associated with mould/bird exposure in this cohort. Conclusion: Group B patients experienced a better outcome compared with (non-exposed) IPF patients, although worse compared with CHP patients. Antifibrotic treatment in group B resulted in a similar beneficial effect compared with group A. Further research is needed to ascertain the diagnostic designation in this exposed usual interstitial pneumonia (UIP) patient group without other CHP features.
INTRODUCTION
Although being regarded as a disease with an unknown cause, a prominent role for certain types of exposure is probable in idiopathic pulmonary fibrosis (IPF) as its incidence is increased in patients exposed to tobacco smoke as well as agriculture/farming, wood and metal dust, asbestos and silica exposure. 1, 2 From a clinical point of view, exposure complicates the differential diagnosis between IPF and exposure-driven interstitial lung diseases (ILD) such as chronic hypersensitivity pneumonitis (CHP) or asbestosis. Although it is accepted that exposure per se does not exclude IPF, a high index of suspicion for CHP is warranted. 3 The lack of internationally accepted guidelines for CHP makes differential diagnosis even more difficult, leading to high interobserver variability and low rates of definite diagnoses. 4, 5 Three recently published papers proposed diagnostic criteria and/or composite score systems to determine the probability of CHP in different clinical scenarios. [6] [7] [8] As treatment of CHP and IPF is different, there is a high medical need for further studies
SUMMARY AT A GLANCE
Usual interstitial pneumonia (UIP) patients exposed to moulds or birds without other features of chronic hypersensitivity pneumonitis (CHP) experience a better survival compared with non-exposed idiopathic pulmonary fibrosis (IPF) patients, although still worse compared with definite CHP patients. A similar beneficial effect from antifibrotics was seen irrespective of mould/bird exposure.
addressing diagnostic and therapeutic aspects of this IPF-CHP differential diagnosis.
We investigated the clinical behaviour of patients with an IPF diagnosis at the multidisciplinary dynamic discussion (MDD) who were exposed to birds (excluding chicken) or moulds and compared these with both non-exposed IPF patients and CHP patients.
METHODS

Patient selection
The ILD database of the University Hospitals Leuven, a tertiary referral centre in Belgium, was analysed, from April 2000 to June 2016, including extensive data on demographics, co-morbidities, high-resolution computed tomography (HRCT), bronchoalveolar lavage (BAL) cell analysis, lung function evolution, mortality and exposure (Table S1 , Supplementary Information). A formal work-up, including (repeatedly) thorough exposure history taking, was performed during standard clinical visits in all ILD patients, with special attention for occupational, recreational and domestic exposures. Diagnosis was based on clinical judgement or an MDD when in doubt, following international guidelines. 9 Ethical approval was obtained from the University Hospitals Leuven Ethical Committee. Familial history was defined as having one family member with pulmonary fibrosis.
Subgroup analysis
Patients diagnosed at the MDD with IPF were divided on the basis of their exposure to birds (chickens excluded) and/or moulds (group A: unexposed patients, group B: exposed patients). Patients diagnosed with CHP in our centre were included in group C. Group B diagnoses were inspected using two proposed diagnostic criteria 6, 7 which were recently published (Table S2 , Supplementary Information). Survival and forced vital capacity (FVC) decline were compared between the groups. Patients were censored on 11 August 2016. Patients undergoing transplantation were censored on the day of transplantation and considered lost to follow-up.
Statistical analysis
Mortality was assessed using a multivariate Cox proportional hazards model, with adjustments for age, gender, ever-smoking, treatment and baseline FVC, as these parameters could influence mortality. Median survival time was presented using a Kaplan-Meier curve. FVC decline between groups A and B was analysed using three different statistical models. The number of patients with FVC decline >10% and >5% after 1 year was compared using a chi-square test. Associations between absolute FVC decline after 12 months and mortality were assessed as well. Furthermore, we compared absolute FVC decline in groups A and B, using an analysis of variance (ANOVA) model. Analysis was performed using R software (CRAN Project, Vienna, Austria), version 3.3.1. P-values <0.05 were considered statistically significant.
RESULTS
Overall, 293 patients were included in the study: 171 group A patients (unexposed patients with an MDD diagnosis of IPF), 73 group B patients (exposed patients with MDD diagnosis of IPF, exposed to: birds, n = 45; moulds, n = 21; both, n = 7), 49 group C patients (CHP diagnosis). There were no differences in baseline characteristics between groups A and B, although group B patients tended to be treated more often with antifibrotics (P = 0.051), as displayed in Table 1 . Groups B and C (CHP group) differed in age, smoking history, familial history, antifibrotic use, percentage of patients with a biopsy and forced expiratory volume in 1 s (FEV 1 ).
To ascertain that CHP was reliably ruled out by the MDD, we inspected group B diagnoses using two recently published papers suggesting a composite score 7 and diagnostic criteria 6 for CHP diagnosis. Although group B patients were more often suspected of HP compared with group A (4 (5.6%) vs 1 (0.6%), P = 0.03), CHP was deemed unlikely by Johansson's criteria in 94.4% of group B patients. 7 Using the Salisbury criteria, 6 four group A patients (2.4%) could be defined as 'HP likely' compared with eight group B patients (11.1%). CHP was ruled out ('HP less likely', according to Salisbury et al.) in only 46 group A (27.2%) and 17 group B patients (23.6%). In five group A and eight group B patients, BAL cell differentials were not available. In 114 group A and 39 group B patients, a biopsy that would have been deemed necessary according to Salisbury et al. was not performed in our cohort. Although group B patients were qualified more often as HP likely compared with group A (P = 0.01), a CHP diagnosis was deemed unlikely in 87.9% of group B patients.
Mortality rate was significantly lower in group B patients compared with group A patients (hazard ratio (HR): 0.48, P = 0.002) (Fig. 1 ). Median survival in group A was 84 months compared with 43 months in group B. Although age, absolute FVC at baseline and antifibrotic use were significant confounders in a multivariate analysis (Table 2) , mould/bird exposure remained an independent factor contributing to better survival (P = 0.037, HR: 0.60). Antifibrotic treatment resulted in a better outcome in group A (HR: 0.44) and group B (HR: 0.12) with no interaction between exposure and antifibrotic use (P = 0.20); antifibrotic treatment effect was similar in groups A and B. No differences in outcome were observed between mould-and birdsexposed group B patients (P = 0.47).
A statistically significant difference was observed between groups C and B (P = 0.037, HR: 0.47): median survival in group B was 84.0 months compared with 156.8 months in group C. Multivariate analysis showed a significant effect of age, antifibrotic use and baseline FVC, while diagnosis remained statistically significant (P = 0.019, HR: 0.39), as shown in Table 3 .
Within the patient cohort with an MDD diagnosis of IPF (combined groups A and B), the evolution of absolute FVC after 1 year was associated with mortality (P = 0.013, HR: 2.8), however this effect was driven by group A (P = 0.037, HR: 2.9). Group B showed no significant effect (P = 0.56). Moreover, FVC decline >10% after 1 year was not associated with mortality, neither in the overall analysis (P = 0.19) nor in the different groups (group B: P = 0.83, group A: P = 0.35). The same was seen for FVC decline >5% (after 1 year) analysis (P-values = 0.98, 0.86 and 0.98, respectively).
Groups A and B experienced a similar FVC evolution (P = 0.77). Furthermore, group A patients experienced FVC decline >10% as frequent as group B patients (21% vs 16%, P = 0.56). The same was true for FVC decline >5% (30.4% vs 29.0%, P = 1.00).
DISCUSSION
We investigated the impact of mould/bird exposure on outcome in a large cohort of patients diagnosed with IPF at MDD. The risk of mortality was significantly lower (HR: 0.48, P = 0.002) in patients exposed to the pre-specified inhalants compared with non-exposed IPF patients. Multivariate analysis confirmed the robustness of this association. Survival in these group B patients was still worse compared with CHP patients (HR: 2.13, P = 0.037). Data are presented as mean AE SD or as patient numbers (%). No statistically significant differences were found between groups A and B. Group C patients were not treated with antifibrotics, as there is no evidence or reimbursement for treatment in this patient group. Pulmonary function data were baseline data at MDD or first clinic visit. Specific IgG results of pigeons and Aspergillus are restrained to patients with exposure to pigeons and fungi, respectively. CT findings were based on imaging at diagnosis. Descriptive statistics were applied to determine demographics of the patient groups. ANOVA models, Student t-tests and Mann-Witney U-tests were used for continuous variables, where applicable. Chi-square tests and Fisher's exact tests were used for categorical variables, where applicable. † In 11 group C patients, a UIP-like CT morphology was present, but-as there were also CHP features present (air trapping, upper lobe morphology, etc.)-these patients could not qualify for 'definite UIP'.
ANOVA, analysis of variance; BAL, bronchoalveolar lavage; CHP, chronic hypersensitivity pneumonitis; CT, computed tomography; DL CO , diffusing capacity of the lung for carbon monoxide; FEV 1 , forced expiratory volume in 1 s; FVC, forced vital capacity; GAP, gender-age-physiology; GGO, ground-glass opacity; MDD, multidisciplinary dynamic discussion; UIP, usual interstitial pneumonia.
As patients suffering from CHP, which is induced by similar exposure (birds and fungi), experience better survival than the general IPF population, we took specific care to ascertain a correct differential diagnosis. 10 First, all group A and B patients were diagnosed during an MDD after formal work-up, including extensive patient history, CT scan, specific IgG against the exposed inhalants and BAL. Second, we meticulously assessed demographics, baseline pulmonary function measurement, BAL lymphocytosis and CT features associated with CHP, between the two IPF subgroups. Group B demographics demonstrate male predominance, high rates of ever-smokers similar to group A with comparable mean age and high rate of familial pulmonary fibrosis which are in line with the current literature. Baseline pulmonary function tests (FVC% and diffusing capacity of the lung for carbon monoxide (DL CO %)) as well as the rate of definite usual interstitial pneumonia (UIP) pattern on CT did not differ, while BAL lymphocytosis was equally low and the presence of diffuse ground-glass opacities, upper lung predominance, a patchy disease distribution, centrilobular noduli, mosaic attenuation and air trapping were equally exceptional. Only the presence of specific IgG antibodies was higher in group B patients compared with group A. As this is believed to be a marker of exposure, rather than disease, this observation does not resolve the IPF-CHP diagnostic conundrum. In contrast, differences between groups B and C were observed in the majority of aforementioned parameters. Third, 35.6% of group B patients were biopsied of whom 96.2% showed a clear UIP image without signs suggestive of CHP. Fourth, we used recently published composite scoring systems 7 and diagnostic criteria 6 to validate these IPF diagnoses: in only 11.1% and 5.6%, group B patients were found 'HP suspect'. We are aware of the recently published paper of Vasakova et al. 8 suggesting a diagnostic management strategy in Figure 1 Kaplan-Meier curve presenting survival as proportion of non-deceased patients. Group B ( ) patients experienced a mortality risk in between group A ( ) and group C ( ) patients. HP. However, as every patient with a fibrotic ILD pattern on HRCT with exposure is (at least) considered as 'possible HP' in this paper, we believe this strategy would not have added diagnostic information to the differential diagnosis in our study. We acknowledge the lack of robust international diagnostic criteria to exclude CHP in patients with an UIP image as well as the high interobserver variability in CHP diagnosis 4 ; nevertheless, as these patients had demographic, radiological, biochemical and histological features distinct of CHP and similar to IPF, we believe it would be erroneous to denominate these patients simply as usual 'CHP patients'. In that context, we would like to stress that no single paper proposing diagnostic criteria for CHP suggests a definite CHP diagnosis in UIP patients only because of a positive exposure: radiographical, immunological (BAL) or pathological features should be present as well.
It is indeed remarkable that the same exposures that are known risk factors for IPF appeared to result in reduced mortality. Although seemingly paradoxical, this combination of increased incidence and lowered mortality is not new in IPF, as it is also seen in IPF patients with gastro-oesophageal reflux (GERD) 11, 12 and some genetic factors (e.g. MUC5B 13 ). Hence, group B patients should not be excluded on this grounds.
In this context, we believe an IPF diagnosis in this patient subgroup is-at this moment-both guidelinesand literature-conform, although we share a concern that this diagnostic designation is not fully indicative of the clinical behaviour of this patient group. We accept that diagnostic designations are dynamic and whether in this future this subgroup should be labelled as IPF with an external factor which impact beneficially on prognosis, or a major fibrotic CHP subgroup, is a semantic discussion which we leave open to the ILD community.
We believe that the relevance of a diagnostic designation should be threefold: (i) to ascertain and communicate the natural history of the disease, (ii) to provide evidence-based treatment options for patients fulfilling the diagnostic designation and (iii) to enable prospective research trials to investigate a patient subgroup experiencing a rather homogeneous disease behaviour including treatment effects. Applied to these group B patients, both an IPF and CHP designation would not fully satisfy these three criteria: (i) prognosis is situated in between (unexposed) IPF and CHP patients; (ii) antifibrotic treatment beneficially impacted both group A and B outcomes (HR: 0.44 and 0.12, respectively) equally (P = 0.20); and (iii) a diagnostic designation of IPF or CHP would hinder researchers to perform prospective research in this enigmatic subgroup: would immune-suppressive treatment be effective in this patient group lacking evidence for disease-related inflammatory activity in HRCT, BAL and pathology? Would a similar treatment effect of antifibrotics between group A and B patients be replicated in prospective trials? These questions can only be answered if these group B patients would be investigated as a distinct patient group. In that sense, we appreciate a certain analogy with Interstitial Pneumonia with auto-immune features (IPAF). Moreover, one could wonder whether-from a pathomechanistical point of view-it would be more accurate to interpret the IPF-CHP differential diagnosis as a continuum rather than two sharply defined entities.
Our study faces some limitations. Analysis of the demographics revealed a trend towards more antifibrotic use in the exposed IPF subgroup versus the non-exposed, although not statistically significant. As this beneficial prognostic impact of exposure remained statistically significant after correction for the use of antifibrotics (in the multivariate analysis), we believe the better survival was indeed attributable to the exposure and not to the use of antifibrotics 14, 15 (only). As the effect of absolute FVC decline on mortality of the global study population is weak and only driven by the non-exposed subgroup, this measurement proved not to be a good parameter for (long term) survival in our cohort. Furthermore, no association with mortality was seen with FVC decline >5% or FVC decline >10% after 1 year. This supports the data of Schmidt et al., 16 questioning the prognostic relevance of FVC decline on longer term. Hence, overall prognostic differences between the two IPF groups of our cohort are not reflected in FVC decline within the first year, as survival rates of both IPF subgroups are similar in the first 2 years after diagnosis.
We acknowledge that-due to regional differences in clinical practice-only one-third of patients were biopsied in groups A and B, which is primarily driven by the fear for exacerbation and mortality. However, reanalysis of the survival data confined to biopsied patients did not alter the main conclusions of the study: same HR were seen, although P-values were attenuated because of decreased statistical power due to lowered n-values (group A vs B: HR: 0.42 (P = 0.058), group B vs C: HR: 0.33 (P = 0.060)). This is a single-centre, retrospective study. As our study was conducted in a tertiary academic centre (with a potential bias towards more sick patients), it is unsure whether patient characteristics (including exposure) can be translated to all IPF patients groups, seen in other centres. Given the favourable median survival rates of 43.3, 84.0 and 156.8 months in the three subgroups (non-exposed IPF patients, exposed IPF patients and CHP patients, respectively), it seems unlikely that our cohort consisted of sicker patients compared with the general IPF population.
Finally, although we actively screened patients for exposure on multiple occasions, it remains a selfreported aspect, potentially resulting in underreporting. As no longitudinal exposure data were available, this study was not able to assess the effect of exposure termination on lung function and/or mortality. Moreover, no data concerning exposure intensity, duration and latency between exposure termination and disease onset were available.
In conclusion, mould-/bird-exposed patients with an MDD diagnosis of IPF experienced a survival situated in between non-exposed IPF patients and CHP patients. Antifibrotic treatment effect in this subgroup appears equally beneficial compared with non-exposed IPF patients. Whether this patient group should be regarded as an IPF subgroup or a major fibrotic CHP subgroup is left open to the ILD community. In our opinion, both diagnostic designations do not fully appreciate the clinical behaviour of this patient group. We believe these patients need to be appreciated as a distinct patient group to allow further prospective research.
